PDS Biotechnology - PDSB Income before deduction of interest, taxes and amortization

Growth for PDS Biotechnology (PDSB) is being driven by the Versamune platform's success in combating HPV-related cancers and the potential for Big Pharma partnerships. The EBITDA figures clearly illustrate the trend, where the parameter value equals 0.00. Meanwhile, PDS Biotechnology (PDSB) is implementing green chemistry principles for sustainable disposal. However, a narrow development profile creates typical biotech risks due to the absence of current sales.

This metric is calculated as operating profit adjusted for depreciation and amortization, which allows for the exclusion of non-cash accounting write-offs and an assessment of the actual scale of generated cash flow. Given the lack of stable revenue at PDS Biotechnology (PDSB), this metric reflects the business's dependence on external financing, making the analysis of EBITDA_Co dynamics critical for monitoring the capital burn rate.